Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Citric acid anhydrous and 13C urea

Drug class: Helicobacter pylori Diagnostic

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Citric acid anhydrous and 13C urea key facts

Drug class
Helicobacter pylori Diagnostic
Used for
IDkit Hp ® One and IDkit Hp ® Two are indicated for use as a diagnostic aid in the initial diagnosis and post-treatment monitoring of Helicobacter pylori (H. pylori) infection in adults and pediatric patients 3 years of age and older. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Latest FDA recall
None listed

Sources: FDA label (July 28, 2026); FDA NDC Directory (November 13, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Citric acid anhydrous and 13C urea used for?
The FDA-approved label (IDkit HP ONE, Meridian Bioscience Israel Ltd, July 28, 2026) says: “IDkit Hp ® One and IDkit Hp ® Two are indicated for use as a diagnostic aid in the initial diagnosis and post-treatment monitoring of Helicobacter pylori (H. pylori) infection in adults and pediatric patients 3 years of age and older. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Citric acid anhydrous and 13C urea?
The “Adverse Reactions” section of the FDA label (IDkit HP ONE, Meridian Bioscience Israel Ltd, July 28, 2026) begins: “The following clinically significant adverse reactions are discussed in the Warning and Precautions section of the labeling: Hypersensitivity Reactions [see Warning and Precautions (5.1)] Adult Patients: The most common adverse reactions (incidence >0.3%) using the IDkit Hp included nausea, throat burning, and lightheadedness. (6.1) Pediatric Patients: The most common adverse reactions (incidence >1.5%) using the IDkit Hp included vomiting.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Citric acid anhydrous and 13C urea?
The “Drug Interactions” section of the FDA label (IDkit HP ONE, Meridian Bioscience Israel Ltd, July 28, 2026) begins: “No formal drug interaction studies were conducted. Information on drugs that may interfere with test results are listed in the Table 1. Table 1: Drugs That Interfere with Test Results Interfering Drug Clinical Effect Prevention or Management Antimicrobials, bismuth-containing preparations May suppress H. pylori or urease activity, leading to false negative results Avoid use within 2 weeks prior to testing.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Citric acid anhydrous and 13C urea have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Citric acid anhydrous and 13C urea?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Citric acid anhydrous and 13C urea been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Citric acid anhydrous and 13C urea?
1 company lists prescription products of Citric acid anhydrous and 13C urea in the FDA NDC Directory, including Meridian Bioscience Israel Ltd.

What Citric acid anhydrous and 13C urea is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

IDkit Hp ® One and IDkit Hp ® Two are indicated for use as a diagnostic aid in the initial diagnosis and post-treatment monitoring of Helicobacter pylori (H. pylori) infection in adults and pediatric patients 3 years of age and older. …

— FDA label: IDkit HP ONE, Meridian Bioscience Israel Ltd, effective July 28, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (solution, oral), IDkit HP ONE, Meridian Bioscience Israel Ltd; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Citric acid anhydrous and 13C urea side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following clinically significant adverse reactions are discussed in the Warning and Precautions section of the labeling: Hypersensitivity Reactions [see Warning and Precautions (5.1)] Adult Patients: The most common adverse reactions (incidence >0.3%) using the IDkit Hp included nausea, throat burning, and lightheadedness. (6.1) Pediatric Patients: The most common adverse reactions (incidence >1.5%) using the IDkit Hp included vomiting.

Read more of this section

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Meridian Bioscience Corporation at 1-800-543-1980 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials Experience and Adverse Reactions in Adult Patients The safety of the IDkit Hp was evaluated in 465 adult patients who participated in two clinical trials (Trial 1 and Trial 2). All patients used the IDkit Hp Two kit for initial diagnosis and post-treatment monitoring of H. pylori infection. The most commonly observed adverse reactions associated with the use of the IDkit Hp were nausea (0.6%), throat burning (0.4%), and lightheadedness (0.4%). Clinical Trials Experience and Adverse Reactions in Pediatric Patients The safety of the IDkit Hp was evaluated in one multi-center, non-randomized, open-label study (Trial 3). A total of 53 pediatric patients, 3 to less than 18 years of age, were enrolled in the study and used the IDkit Hp Two. The only adverse reaction reported was vomiting (2%). 6.2 Post-marketing Experience In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during post-marketing use of the IDkit Hp One and IDkit Hp Two based on patient and test administrator reports. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal: Nausea, vomiting, abdominal pain, diarrhea General: Sweating, throat pain, malaise Immune: Anaphylactic reaction Neurologic: Dizziness, headache 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials Experience and Adverse Reactions in Adult Patients The safety of the IDkit Hp was evaluated in 465 adult patients who participated in two clinical trials (Trial 1 and Trial 2). All patients used the IDkit Hp Two kit for initial diagnosis and post-treatment monitoring of H. pylori infection. The most commonly observed adverse reactions associated with the use of the IDkit Hp were nausea (0.6%), throat burning (0.4%), and lightheadedness (0.4%).

— FDA label: IDkit HP ONE, Meridian Bioscience Israel Ltd, effective July 28, 2026. This is part of the section. Read the full label on DailyMed →

Citric acid anhydrous and 13C urea drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

No formal drug interaction studies were conducted. Information on drugs that may interfere with test results are listed in the Table 1. Table 1: Drugs That Interfere with Test Results Interfering Drug Clinical Effect Prevention or Management Antimicrobials, bismuth-containing preparations May suppress H. pylori or urease activity, leading to false negative results Avoid use within 2 weeks prior to testing.

Read more of this section

If used within 2 weeks, postpone testing until at least 2 weeks after discontinuation. Proton pump inhibitors (PPIs) May reduce urease activity or alter gastric conditions, potentially causing false negative results. A positive result during PPI use may still indicate H. pylori presence. Avoid use within 2 weeks prior to testing. If a negative result is obtained during PPI use, repeat the test 2 weeks after PPI discontinuation. Antimicrobials, Bismuth-containing preparations: Avoid use within 2 weeks prior to testing. (7) Proton pump inhibitors (PPIs): Avoid use within 2 weeks prior to testing. (7)

Table from the label
Interfering DrugClinical EffectPrevention or Management
Antimicrobials, bismuth-containing preparationsMay suppress H. pylori or urease activity, leading to false negative resultsAvoid use within 2 weeks prior to testing.If used within 2 weeks, postpone testing until at least 2 weeks after discontinuation.
Proton pump inhibitors (PPIs)May reduce urease activity or alter gastric conditions, potentially causing false negative results.A positive result during PPI use may still indicate H. pylori presence.Avoid use within 2 weeks prior to testing.If a negative result is obtained during PPI use, repeat the test 2 weeks after PPI discontinuation.

— FDA label: IDkit HP ONE, Meridian Bioscience Israel Ltd, effective July 28, 2026. Read the full label on DailyMed →

Citric acid anhydrous and 13C urea dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

IDkit Hp One and IDkit Hp Two each contain a 75 mg 13 C-urea tablet for oral solution, and 4 g Citrica (citric acid) for oral solution along with other materials for use with the BreathID system device (2.1, 16) o IDkit Hp One is co-packaged with a nasal canula to be used with the BreathID system device as identified in the BreathID system device labeling.

Read more of this section

(2.1) o IDkit Hp Two is co-packaged with breath sample bags to be used with the BreathID system device as identified in the BreathID system device labeling. (2.1) To prepare the oral solution for either kit, dissolve the 13 C-urea tablet and the Citrica (citric acid) for oral solution in 150 to 200 mL of water to provide a clear, colorless solution for oral administration. The resulting solution is ingested by the patient. (2.3) See full prescribing information for detailed important instructions concerning preparation, administration, and disposal of IDkit Hp One and IDkit Hp Two. (2.3 - 2.6) See BreathID ® system device manual for additional details for use of IDkit Hp One and IDkit Hp Two with the BreathID system device, including troubleshooting device malfunction. (2.2) 2.1 Dosage and Administration Overview IDkit Hp One or IDkit Hp Two contain the same drug product, 75 mg 13 C-urea tablet and 4 g Citrica (citric acid) for oral solution and follow the same drug preparation and administration instructions. IDkit Hp One and IDkit Hp Two are to be administered only by trained personnel as ordered by a licensed healthcare practitioner, using the BreathID system device that as identified in the BreathID system device labeling, is intended for use with IDkit Hp One and IDkit Hp Two. For in vitro diagnostic use only. Inform the patient that each 4 g packet of Citrica (citric acid) for oral solution contains 84 mg of phenylalanine per dose. Phenylketonurics restrict dietary phenylalanine [see Warnings and Precautions (5.2)]. The patient should have fasted for at least one hour before administering the test drink. The patient should not have taken antimicrobials, proton pump inhibitors (PPI), or bismuth preparations within two weeks prior to administering the test. If PPIs are used within two weeks of breath testing, false negative test results may occur, and the test should be repeated two weeks after discontinuation of PPI treatment. A positive result for a patient on PPI could be considered as indicative of the presence of urease enzyme associated with H. pylori.

— FDA label: IDkit HP ONE, Meridian Bioscience Israel Ltd, effective July 28, 2026. This is part of the section. Read the full label on DailyMed →

Citric acid anhydrous and 13C urea in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Published data from other single oral dose 13 C-urea breath test kits containing urea and citric acid have not demonstrated a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. There are no available data on the use of IDkit Hp One or IDkit Hp Two use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.

Read more of this section

There are no animal data that meet current standards for nonclinical developmental toxicity studies. Based on available literature, no significant developmental or reproductive toxicities were observed in nonclinical studies with urea or citric acid. A single oral dose of 13 C-urea and citric acid at the maximum recommended human dose (MRHD) are unlikely to pose a significant developmental or reproductive risk, since humans typically have higher circulating levels of urea, and citric acid exposure from the test is within the range of normal dietary intake. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

— FDA label: IDkit HP ONE, Meridian Bioscience Israel Ltd, effective July 28, 2026. Read the full label on DailyMed →

When Citric acid anhydrous and 13C urea should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

IDkit Hp One and IDkit Hp Two are contraindicated in patients with a known hypersensitivity to the 13 C-urea, Citrica (citric acid) or to any of the excipients [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)]. Hypersensitivity to the 13 C-urea, Citrica (citric acid) or to any of the excipients in the drug. (4)

— FDA label: IDkit HP ONE, Meridian Bioscience Israel Ltd, effective July 28, 2026. Read the full label on DailyMed →

Forms and how it is given

Dosage formsSolution
RouteOral
Prescription products1 in the FDA NDC Directory
Brand namesIdkit Hp One

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA021314
IDKIT:HP
Meridian BioscienceDecember 17, 2002 6, latest July 24, 2026
2026: Efficacy · 2016: Manufacturing (CMC) · 2016: Manufacturing (CMC)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

SPL set ID of the quoted label8baab7a7-5d20-46ad-9c4a-762992ef6b51
FDA labels (SPL)1
FDA applicationsNDA021314
Active ingredients (FDA)CITRIC ACID MONOHYDRATE / UREA C-13

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — IDkit HP ONE, Meridian Bioscience Israel Ltd, effective July 28, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers